Pharmaceutical Stone Technology (stock code: 300725), as a global leader in pharmaceutical R&D and manufacturing, provides one-stop services from molecular block development to drug discovery solutions. The company focuses on chemical and low-carbon technology innovation, and is committed to improving the efficiency of new drug discovery and development while reducing drug production costs. Yakshi Technology's molecular block library is rich in variety, novel in structure and efficient, and has successfully covered many key stages of new drug development.

In terms of assets and liabilities, Yakshi Technology's 2023 three-quarter report shows that the company's total assets reached 5.217 billion yuan, an increase of 7.29% over 4.862 billion yuan at the end of the previous year. Total liabilities were $2,408 billion, up 9.19% from $2.205 billion at the end of the previous year. Net assets increased by 5.69% to 2,809 billion yuan at the end of last year to 2,809 billion yuan. The balance ratio rose slightly, from 45.34% at the end of the previous year to 46.15%, indicating that the company's financial structure is relatively stable.

In terms of profit, Yakshi Technology's revenue increased from 1,185 billion yuan in the same period last year to 1,291 billion yuan, with a growth rate of 9.01%. However, operating profit and net profit performance were not as good as operating income, falling to 138 million yuan and 154 million yuan respectively in the same period last year. Gross margin and net margin also declined, falling to 42.88% and 11.93%, respectively, from 47.3% and 22.06% in the same period last year. These changes may be related to an increase in operating costs, which rose from 624 million yuan in the same period last year to 738 million yuan.

In terms of cash flow, the net cash flow from Yakshi Technology's operating activities was $149 million, a decrease of 20.31% compared with 186 million yuan in the same period last year. Although the subtotal cash inflow from operating activities increased from 1,229 billion yuan to 1,258 billion yuan in the same period last year, cash outflow from operating activities also increased from 1,042 billion yuan to 1.11 billion yuan.

Taken together, Yakushi Technology maintained steady asset growth in the third quarter of 2023, but there was a certain decline in profit and cash flow. This may reflect the challenges of cost control and efficiency improvement while increasing operating income.

For investors, Yakushi Technology's financial report shows the company's strong competitiveness and market position in pharmaceutical R&D and manufacturing. Despite recent declines in profit and cash flow, the company's overall asset quality remains good, and operating income continues to grow. When considering investing in Yakshi Technology, investors should pay close attention to the company's future cost control strategies and market expansion plans, and how these factors affect the company's long-term profitability.

This article only represents the judgments made by analysts themselves or analysts based on AI analysis. It cannot be used as an investment indicator, nor does it constitute any investment advice. The original purpose of this article was to help investors analyze and judge capital market data in the most intuitive and fastest way and from the most professional perspective.